An observational study in Malaria, sponsored by Bernhard Nocht Institute for Tropical Medicine. Recruiting at 1 site in Ghana. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-09-01.
Sponsored by Bernhard Nocht Institute for Tropical Medicine · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies in Malaria with a site in Ghana — 5 open to participants now, 6 under way, none of them phase 3. Malaria · Ghana.
Among the 59 studies in Malaria with a site in Ghana, this one is the 6th largest by planned enrollment of the 11 observational ones that give a count, is one of 3 that started in 2019, is one of 11 observational ones, and was the 50th registered.
1,187 studies on the registry are indexed under Malaria; 80 are open to participants now.
Browse Malaria studies →5 of the 59 studies in Malaria with a site in Ghana are open now. Recruiting first, the newest first:
University of Michigan · Sites in Ghana
Ages 15–49 · Women only · Healthy volunteers
Novartis Pharmaceuticals · Sites in Ghana, Burkina Faso, Côte D'Ivoire and 3 more countries
Ages 2–100
Noguchi Memorial Institute for Medical Research · Sites in Ghana
Ages 3 mo+ · Healthy volunteers
Kintampo Health Research Centre, Ghana · Sites in Ghana, Kenya, Malawi
Ages 6 mo–59 mo
A study can be open while its sites in Ghana have not opened yet or have stopped. Only those recruiting at a site in Ghana →
Of the 51 Malaria studies recruiting now, 15 (29%) set no upper age limit and 33 (65%) stop at 75 or younger; 37 take children under 18; 31 take healthy volunteers.
This study: 18 Years and older · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 3 15 · Phase 4 12
First in 2000; this study’s year is marked. 3 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,800 is above the median of 578 across 205 observational studies indexed under Malaria.
Median enrollment 1,490 across the 47 interventional studies, 1,800 across the 11 observational. Of the 48 that completed or were terminated, 16 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 59 have an industry lead sponsor. The 10 most frequent:
Bernhard Nocht Institute for Tropical Medicine is the lead sponsor of 10 studies on the registry; 2 are open to participants now.
Bernhard Nocht Institute for Tropical Medicine has 2 studies filed under Malaria — fewer than ten, so there is no comparison to draw.
1 of the studies in Malaria with a site in Ghana that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07389057Noguchi Memorial Institute for Medical ResearchAssessing the Feasibility of Combining Dihydroartemisinin Piperaquine and Primaquine for Malaria Mass Drug Administration in High Endemic Communities in the Eastern Region of Ghana | 2026-11-30 |
Add it to your calendar (.ics) → With an account.
Among the 59 studies in Malaria with a site in Ghana, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Malaria is a major health threat worldwide with an estimated 229 million cases and 409,000 deaths in 2019 (WHO, World Malaria Report 2019). Vulnerable are young children and pregnant women. The study aims to investigate immunity development against malaria with regard to parasite, human, and socioeconomic factors and possible correlations with pathology or protection in a prospective birth cohort.
Malaria during pregnancy poses substantial risks for the mother and her foetus. Due to the risk of malaria during early childhood, the study addresses the high malaria morbidity and mortality in young children. Though recognised as a public health issue, it has still not been well understood how clinical immunity against malaria parasites develops, which parasite and host factors play a role in infection susceptibility, and why some infections proceed to develop severe complications while others resolve after a mild disease.
In order to identify interactions between parasite and host, a longitudinal study is performed starting with the recruitment of pregnant women. The study is conducted in Agogo in Ghana, an area with high malaria endemicity. The study design allows to analyse the neonatal immune status at birth, after potential in-utero exposure, and follows the development of immunity over the first 36 months of life. The current paradigm is that time points and frequency of infection as well as the type of variant surface antigen expressed have an impact on the cellular and humoral immune response to malaria, the development of clinical immunity, as well as the risk for future complications.
Starting point of the study is the antenatal care visit of mothers at Agogo Presbyterian Hospital (APH) during pregnancy. During recruitment, the mother will be asked to read and sign an informed consent form approved by the local ethical committee. After consent has been obtained from the mother, biological samples are taken, and a case report form is filled. An identification card with a unique code number is handed out. The first follow-up visit occurs at the birth of the child. At this time point, samples are taken from the mothers and the child. Mothers/primary caregivers are invited to observe the EPI visits offered at their nearest health post for further follow-ups. In the first year after birth, the EPI schedule includes visits at six weeks, ten weeks, 14 weeks, six months, and nine months. During these visits, questionnaires are completed and stool samples are taken. In the first six weeks after birth, the household is visited to complete a household questionnaire including housing characteristics and household assets. Additionally, a women's questionnaire is administered, which collects demographic and socioeconomic background characteristics as well as health and related behavioural data. At 12, 18, 24, and 36 months after birth, mothers/primary caregivers are encouraged to bring their children to the study hospital (APH) for a medical check-up. For the period of 36 months after birth, mothers/primary caregivers are strongly encouraged to visit the study hospital (APH) every time the child experiences a febrile illness or a history of fever in the last week during the observation period.
Pregnant women visiting Agogo Presbyterian Hospital (APH) for their antenatal care visit and the newborn children born to these mothers
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
900 mothers recruited during pregnancy
900 children born to the recruited mothers
Malaria episodes
Frequency and severity of malaria episodes as identified by microscopy, PCR, and clinical criteria.
Time frame: First 36 months of life
T cell repertoire
T cell repertoire as measured by FACS analysis
Time frame: First 36 months of life
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2019 (actual). Primary completion is estimated for Apr 2025, 72 months after the start.
Of 85 non-industry observational studies under Malaria, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 36. This study's planned 72 months is above that.
Counting every sponsor, half of 93 studies reached it within 24 months; a quarter within 16 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bernhard Nocht Institute for Tropical Medicine